BiotechTube

elagolix + estradiol/norethindrone acetate (E2/NETA)

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis

Conditions

Endometriosis

Trial Timeline

Dec 27, 2017 → Oct 23, 2018

NCT ID
NCT03343067

About elagolix + estradiol/norethindrone acetate (E2/NETA)

elagolix + estradiol/norethindrone acetate (E2/NETA) is a phase 3 stage product being developed by AbbVie for Endometriosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03343067. Target conditions include Endometriosis.

What happened to similar drugs?

1 of 18 similar drugs in Endometriosis were approved

Approved (1) Terminated (2) Active (15)
✅Decapeptyl SR 11.25mgIpsenApproved
🔄40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
🔄Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
🔄Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
🔄ElagolixAbbViePhase 3
🔄ElagolixAbbViePhase 3
🔄elagolixAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03343067Phase 3Terminated

Competing Products

20 competing products in Endometriosis

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
35
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
47
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
29
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
32
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
29
Placebo + ElagolixAbbViePhase 2
35
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
44
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
40
ElagolixAbbViePhase 3
40
Elagolix + placeboAbbViePhase 2
35
ElagolixAbbViePhase 3
40
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
35
elagolixAbbViePhase 3
40
ElagolixAbbViePhase 3
40
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
35
Gefapixant + Placebo + NaproxenMerckPhase 2
35
BGS649 + PlaceboNovartisPhase 2
27
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
35
LetrozoleNovartisPhase 2
35